AbbVie v Amgen: Is the “patent dance” fair for both sides?
Abbvie suing Amgen over its efforts to launch a Humira biosimilar is the first instance of parties not agreeing on which patents to be litigated under the BPCIA. The case poses the question of whether the patent dance strikes the right balance between parties
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: